Gosh, it’s been a busy few weeks! Our news cycle has been dominated by Lykos Therapeutics-related stories, from ICER’s report and panel meeting through to FDA’s Advisory Committee meeting and yesterday’s patent-related news.
Elsewhere in the psychedelics field, things have been a little quieter; especially for this author who was unable to attend the sixth edition of the Interdisciplinary Conference on Psychedelic Research (ICPR) in Haarlem.
Despite psychedelics companies taking a backseat on the news front as they let Lykos soak up the limelight—for better or worse—there are several headlines to share.
Let’s get you up to speed…
***
In this Issue
- Lykos, Lykos, Lykos…
- A First Look at EPIsoDE Trial Results
- European Drug Report Briefly Discusses Psychedelics’ Potential Therapeutic Uses, Risks
- DEA Should Improve Religious Exemption Petition Process, Says U.S. Government Accountability Office
- Other Stories
Sign-in or join Pα+ to continue reading…
Independent data-driven reporting, analysis and commentary on the psychedelics space: from business and drug development through to policy reform and culture.
Already a member? Log In
✓ Regular Bulletins covering key topics and trends in the psychedelics space
✓ Regular articles and deep dives across psychedelic research, policy and business
✓ Interviews with insiders
✓ Monthly interactive database and commentary on psychedelic patents
✓ Quick-take analysis of major developments
✓ A Library of primers and explainers
✓ Access to our full back catalogue